ctDNA-based molecular residual disease and survival in resectable colorectal cancer
Nakamura, et al. Nature Medicine 2024
Read More
Signatera
Resources related to Signatera residual disease testing from a simple drop of blood.
-
-
From Detection to Decision-Making: Utility of Signatera in Complex GI & Hepatobiliary Malignancies
Watch Video
-
Multi-Institutional Study Evaluating the Role of Early Circulating Tumor DNA Dynamics During Treatment With Immune Checkpoint Inhibitors in
Ma VT., Zhou AY., Forati A., et al. JCO PO 2026
Read More
-
Longitudinal ctDNA monitoring for post-surgical disease surveillance in patients with stage I-IIIB melanoma
Ansstas G., Khaddour K., Sudhaman S., et al. CCR. 2026
Read More
-
Sensitivity of Circulating Tumor DNA for Detection of Minimal Residual Disease Recurrence or Relapse in Patients With Melanoma
Steimle AK., Harris MS, Forati A, et al. JCO OA. 2026
Read More
-
Circulating Tumor DNA Predicts Response After Definitive Radiation Therapy for Merkel Cell Carcinoma
Murchison, K., Camargo, A., Margalit, D., et al. Adv. Radiat. Oncol. 2026
Read More
-
Genomic profiling guided therapy for synchronous SCC and CLL of the parotid gland: a rare case report
Dahiya, R., Weiss, N., Wilson, P., et al. J Surg Case Rep. 2025
Read More
-
Personalized Circulating tumor DNA assay to assess long-term clinical benefit in patients with advanced melanoma
Martinez-Villa C, Teixido C, Martin R, et al. Cancers 2025
Read More
-
Circulating tumor DNA level is associated with time to clinical recurrence in Merkel cell carcinoma: Implications for patient management
Akaike T, Thakuria M, Silk AW, et al. J Am Acad Dermatol. 2025
Read More
-
ctDNA Dynamics Identifies Pseudoprogression in a Metastatic Melanoma Patient Treated With Nivolumab/Relatlimab
Steimle AK, Cho SY, Menon N, et al. Journal of Immunotherapy 2025
Read More
-
Circulating Tumor DNA in High‐Risk Stage II/III Cutaneous Melanoma: A Feasibility Study
Rhodin KE, O’Connor MH, Therien A, et al. Ann. Surg. Oncol. 2025
Read More
-
Expanded eligibility for Natera’s Financial Assistance Program
Read Article
-
Dynamics of Tumor-informed Circulating Tumor DNA and Association with Clinical Responses to Enfortumab and Pembrolizumab in Patients with Lo
. Vlachou, B.A. Johnson 3rd, M. Kates et al, Eur Urol Open Sci (2025)
Read More
-
Dr. Ari Rosenberg SINERGY Data Summary
Dr. Ari Rosenberg from the University of Chicago gives a summary on the SINERGY Trial data that he presented during an oral plenary session at MHNCS.
Watch Video
-
Molecular Residual Disease and Recurrence in Rectal Cancer Patients Undergoing Upfront Surgery: A Prospective Cohort Study
Ando K, Hamabe A, Nakamura Y, et al. Ann Surg. 2026
Read More
-
What ASCO GI 2026 Means for Patients: How MRD Research Is Shaping GI Cancer Care
Read Article
-
Utility of Circulating Tumor DNA to Assess Tumor Response in Patients with Locally Advanced Rectal Cancer Undergoing Neoadjuvant Therapy
Chakrabarti S, et al. Cancers. 2026
Read More
-
Alteration of the Tumor Microenvironment With Intratumoral Dendritic Cells Before Chemotherapy in ERBB2 Breast Cancer A Nonrandomized Clinic
Han, H.S. et al; JAMA Oncology 2025
Read More
-
Adjuvant endocrine therapy with cyclindependent kinase 4/6 inhibitor, ribociclib, for localized hormone receptor-positive/ HER2– breast canc
Spring L. M. et al; npj Breast Cancer 2025
Read More
-
Personalized Circulating Tumor DNA Testing for Detection of Progression and Treatment Response Monitoring in Patients With Metastatic Invasi
Foldi J; JCO Precision Oncology 2025
Read More
-
Loading More...
